Cargando…
Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study
We aimed to evaluate the effectiveness and safety of dronedarone versus sotalol in real-world practice in Asian patients with atrial fibrillation (AF). Using the Korean nationwide claims database from August 2013 to December 2016, we identified patients with AF recently prescribed dronedarone or sot...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527331/ https://www.ncbi.nlm.nih.gov/pubmed/32999348 http://dx.doi.org/10.1038/s41598-020-73115-y |
_version_ | 1783589033187737600 |
---|---|
author | Lee, So-Ryoung Choi, Eue-Keun Kim, Ji-Hyun Kim, Jung-Ae Kwon, Tae-Yeon Lee, Young Eun Oh, Seil |
author_facet | Lee, So-Ryoung Choi, Eue-Keun Kim, Ji-Hyun Kim, Jung-Ae Kwon, Tae-Yeon Lee, Young Eun Oh, Seil |
author_sort | Lee, So-Ryoung |
collection | PubMed |
description | We aimed to evaluate the effectiveness and safety of dronedarone versus sotalol in real-world practice in Asian patients with atrial fibrillation (AF). Using the Korean nationwide claims database from August 2013 to December 2016, we identified patients with AF recently prescribed dronedarone or sotalol and analyzed the hospitalization risk and all-cause death until December 2017. Overall, 3119 and 1575 patients treated with dronedarone and sotalol, respectively, were included. After propensity score weighting, no significant differences were observed between the treatment groups. Dronedarone use was associated with a lower risk of all-cause hospitalization than sotalol use (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.70–0.88). The dronedarone group demonstrated a significantly lower risk of cardiovascular (CV) hospitalization than the sotalol group (HR 0.62, 95% CI 0.53–0.72); however, no significant difference was observed in non-CV hospitalization. No difference in the risk of all-cause death was observed between groups. The dronedarone group was significantly less likely to receive nonpharmacological treatment for AF than the sotalol group (HR 0.63, 95% CI 0.51–0.77). In a large-scale population of Asian patients with AF, dronedarone was associated with a lower risk of CV hospitalization and a lower need for nonpharmacological treatment for AF than sotalol. |
format | Online Article Text |
id | pubmed-7527331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-75273312020-10-01 Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study Lee, So-Ryoung Choi, Eue-Keun Kim, Ji-Hyun Kim, Jung-Ae Kwon, Tae-Yeon Lee, Young Eun Oh, Seil Sci Rep Article We aimed to evaluate the effectiveness and safety of dronedarone versus sotalol in real-world practice in Asian patients with atrial fibrillation (AF). Using the Korean nationwide claims database from August 2013 to December 2016, we identified patients with AF recently prescribed dronedarone or sotalol and analyzed the hospitalization risk and all-cause death until December 2017. Overall, 3119 and 1575 patients treated with dronedarone and sotalol, respectively, were included. After propensity score weighting, no significant differences were observed between the treatment groups. Dronedarone use was associated with a lower risk of all-cause hospitalization than sotalol use (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.70–0.88). The dronedarone group demonstrated a significantly lower risk of cardiovascular (CV) hospitalization than the sotalol group (HR 0.62, 95% CI 0.53–0.72); however, no significant difference was observed in non-CV hospitalization. No difference in the risk of all-cause death was observed between groups. The dronedarone group was significantly less likely to receive nonpharmacological treatment for AF than the sotalol group (HR 0.63, 95% CI 0.51–0.77). In a large-scale population of Asian patients with AF, dronedarone was associated with a lower risk of CV hospitalization and a lower need for nonpharmacological treatment for AF than sotalol. Nature Publishing Group UK 2020-09-30 /pmc/articles/PMC7527331/ /pubmed/32999348 http://dx.doi.org/10.1038/s41598-020-73115-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Lee, So-Ryoung Choi, Eue-Keun Kim, Ji-Hyun Kim, Jung-Ae Kwon, Tae-Yeon Lee, Young Eun Oh, Seil Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study |
title | Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study |
title_full | Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study |
title_fullStr | Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study |
title_full_unstemmed | Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study |
title_short | Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study |
title_sort | comparative clinical outcomes of dronedarone and sotalol in asian patients with atrial fibrillation: a nationwide cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527331/ https://www.ncbi.nlm.nih.gov/pubmed/32999348 http://dx.doi.org/10.1038/s41598-020-73115-y |
work_keys_str_mv | AT leesoryoung comparativeclinicaloutcomesofdronedaroneandsotalolinasianpatientswithatrialfibrillationanationwidecohortstudy AT choieuekeun comparativeclinicaloutcomesofdronedaroneandsotalolinasianpatientswithatrialfibrillationanationwidecohortstudy AT kimjihyun comparativeclinicaloutcomesofdronedaroneandsotalolinasianpatientswithatrialfibrillationanationwidecohortstudy AT kimjungae comparativeclinicaloutcomesofdronedaroneandsotalolinasianpatientswithatrialfibrillationanationwidecohortstudy AT kwontaeyeon comparativeclinicaloutcomesofdronedaroneandsotalolinasianpatientswithatrialfibrillationanationwidecohortstudy AT leeyoungeun comparativeclinicaloutcomesofdronedaroneandsotalolinasianpatientswithatrialfibrillationanationwidecohortstudy AT ohseil comparativeclinicaloutcomesofdronedaroneandsotalolinasianpatientswithatrialfibrillationanationwidecohortstudy |